A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
Conditions: NSCLC Interventions: Drug: BPI-1178; Drug: Osimertinib Sponsors: National Cancer Center, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | China Health | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study